8-K filing — VOLITIONRX LTD (VNRX)
Filed: 2026-09-15 AccNo: 0001477932-26-005620 Size: 137 KB Item 3.02: Unregistered Sales of Equity Securities
Stocks · News reference
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated
VolitionRX shares are trading lower after the company filed a prospectus for an offering of 10 million shares.
Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders
SEC.